配售事项的最高所得款项总额将约为592万港元。配售事项的最高所得款项净额将约为540万港元，将用 作当前业务营运、发展以及一般营运资金的支出。 10月15日，惠陶集团发布公告称，于2025年10月15日，公司拟配售最多1741.6万股配售股份，相当于经 配售事项扩大后的已发行股份总数约16.66%。配售价0.34港元较10月15日收市价每股0.425港元折让约 20%。 智通财经APP获悉，香港联交所最新资料显示，10月21日，惠陶集团(08238)股东将股票由致富证券转入 富途证券国际香港，转仓市值122.77万港元，占比5.78%。 ...

Core Insights - Hong Kong Stock Exchange data indicates that on October 21, 2023, shareholders of Zhongbo Data (00471) deposited shares into Jinlifeng Securities, with a market value of HKD 4.8 million, representing 6.67% of the total [1] Company Actions - Zhongbo Data announced the placement and issuance of 19.0639 million new shares, with the subscription completed on September 18, 2025 [1]

Core Viewpoint - The recent stock placement by Shengbo Holdings has been successfully completed, with significant participation from multiple investors, indicating strong market interest in the company [1] Group 1: Stock Placement Details - On October 21, shareholders of Shengbo Holdings deposited shares into Dingpei Securities, with a market value of HKD 24.2151 million, representing 20% of the total [1] - The placement agreement conditions have been met, and the placement was completed on October 21, 2025, in accordance with the terms of the agreement [1] - The placement agent successfully issued a total of 127 million shares at a placement price of HKD 0.137 per share to no fewer than six investors [1] Group 2: Financial Outcomes - The net proceeds from the placement amount to approximately HKD 16.87 million [1] - The net placement price per share is approximately HKD 0.1324 [1]

GIC是新加坡最大的国际投资机构之一，管理新加坡政府的大部分金融资产，并进行长期投资，旨在保 持和提高资金的国际购买力。公开资料显示，GIC目前管理资金规模超过8000亿美元。 以"长期价值投资"著称的GIC，其投资方向往往被视为重要风向标。此次大手笔增持和铂医药，无疑是 对该公司技术实力、管线潜力以及商业前景的认可。 近日，澳大利亚知名投资机构Simply Wall St在发布的一篇名为《亚洲市场三大"潜力黑马"》（Three Undiscovered Gems In Asia With Strong Potential）的报告中提及和铂医药。报告指出，作为生物科技企 业，和铂医药一年来收入激增243%，远超行业增速，但市盈率仍低于生物科技行业平均水平，未来具 有很大的增长潜力。 （文章来源：证券时报网） 新加坡投资巨头再次增持和铂医药！ 10月21日，港交所披露的信息显示，新加坡政府投资基金（GIC）于10月16日以每股均价13.5791港元的 价格，增持和铂医药69万股。以此计算，GIC此次增持斥资约937万港元。此次增持后，GIC持有和铂医 药6297.5万股，好仓比例从6.97%提升至7.05%。 ...

信达生物表示，公司将获得12亿美元的首付款，包括以认购事项方式获得的1亿美元的战略股权投资。 公司亦有权获得合计最高可达102亿美元的潜在里程碑付款，本次合作交易总金额最高可达114亿美元。 公司还将获得每个候选药物在大中华区以外的潜在销售分成，除IBI363在美国市场双方将采用利润损失 共担模式。 根据合作，信达生物与武田制药将在全球范围内共同开发新一代IO基石疗法IBI363，并在美国共同商业 化，武田制药将在共同治理和协同一致的开发计划下主导相关工作；同时，信达生物授予武田制药 IBI363在除大中华区及美国地区的商业化权益。信达生物授予武田制药IBI343在大中华区以外地区的独 家权益。此外，信达生物授予武田制药IBI3001在大中华区以外地区权益的独家选择权。 信达生物早间在港交所公告，于2025年10月22日（香港时间），信达生物与武田制药达成全球战略合 作，旨在加速推进信达生物新一代IO及ADC疗法开发。本次合作包括两款后期在研疗法IBI363及 IBI343，以及一款早期研发项目IBI3001的选择权。 ...

Core Insights - The company has initiated the clinical trial of GFH375, a KRAS G12D inhibitor, for treating advanced solid tumors, marking a significant step in its clinical development [1][2] - The trial, approved by the National Medical Products Administration, aims to evaluate the safety, efficacy, and pharmacokinetics of GFH375 in combination with chemotherapy and cetuximab [1] - GFH375 has shown promising results in preclinical studies and has received fast track designation from the FDA for treating advanced KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) [2] Group 1 - GFH375's clinical trial (GFH375X1202) has commenced with the first patient enrolled at Peking University Cancer Hospital [1] - The trial will be conducted at approximately 15 centers, focusing on the safety and efficacy of GFH375 in combination with either cetuximab or chemotherapy [1] - The Phase II trial will specifically target first-line treatment for advanced PDAC and colorectal cancer (CRC) patients [1] Group 2 - Dr. Wang Yu, Chief Medical Officer, expressed optimism about advancing GFH375 into frontline PDAC treatment, highlighting its potential across multiple tumor types [2] - The single-agent study of GFH375 is set to begin in June 2024, with promising data already presented at major oncology conferences [2] - GFH375 is a highly selective oral small molecule that inhibits KRAS G12D, effectively disrupting downstream signaling pathways and tumor cell proliferation [2] Group 3 - The company has entered into a licensing and early collaboration agreement with Verastem for three RAS/MAPK-driven cancer products [3] - Verastem has chosen GFH375/VS-7375 as the lead project, granting them exclusive rights outside Greater China upon achieving specific clinical milestones [3] - The licensing agreement allows Verastem to develop and commercialize GFH375 outside of China, while the company retains rights within the country [3]

Core Insights - The commercial real estate sector is undergoing a structural change rather than a cyclical one, with a shift from a "buy-buy-buy" mentality to addressing unmet spiritual and social needs [1] - The upcoming peak in shopping center openings is expected around the National Day holiday in 2025, with over 60 projects set to launch nationwide [1] Industry Trends - The golden era of commercial real estate appears to be fading, with increasing homogenization and significant pressure on the sector due to slow recovery in employment and income expectations [2] - Developers are adapting to the new market dynamics by focusing on strategic adjustments while maintaining a stable operational approach [2] Developer Strategies - Developers are shifting from traditional land acquisition and rapid construction to urban renewal projects due to high land costs and intense competition [4][6] - Companies like 恒隆集团 (Hang Lung Group) are focusing on deep participation in urban renewal to maximize asset value rather than merely engaging in light asset output [4][6] Market Opportunities - Despite challenges, there are still significant opportunities in the commercial real estate sector, particularly in second-tier cities where consumer demand is expected to grow [8][10] - The focus on community development and strategic partnerships is seen as a way to enhance business resilience and expand market presence [7][10] Financial Considerations - The recovery of the real estate market is anticipated to be gradual, influenced by global interest rates and local economic conditions [13][14] - Companies are prioritizing debt reduction and maintaining liquidity to navigate the current market uncertainties [15]

智通财经APP获悉，港股创新药企云顶新耀(01952)10月21日召开公司发展战略投资者交流会。董事会荣 誉主席傅唯、董事会主席及执行董事吴以芳、执行董事及首席执行官罗永庆、执行董事、总裁及首席财 务官何颖等核心管理团队出席，系统介绍了公司最新战略规划、研发进展及中长期发展蓝图。 在自主研发方面，公司依托领先的mRNA肿瘤治疗性疫苗平台与自体生成CAR-T平台，持续夯实自研技 术壁垒，并积极布局眼科等高成长蓝海领域，为中长期发展开辟新增长曲线。其中，拥有全球权益的新 一代共价可逆BTK抑制剂EVER001（希布替尼）在52周完整数据展现出快速、深度且持久的免疫学和 临床缓解，停药后仍持续获益，部分患者在扩展随访期最长至104周数据保持了良好维持效果，体现出 希布替尼的高安全性，及强耐受性。该项目已完成临床POC（概念验证），计划于2026年启动pMN关 键注册性临床及II期篮式试验（包含IgAN、FSGS、MCD）。同时，公司自体生成CAR-T项目已完成非 人灵长类动物（猴）模型（NHP）的临床前概念验证，计划于2025年底前启动人体临床（FIH，首次人 体试验）研究， 并将于2026年递交全球IND（新药临 ...

智通财经APP获悉，近期，出险房企的化债迎来密集突破。10月16日，旭辉(00884)发布公告，披露其境 外债务重组方案的具体细节及公司将采取的相关措施，包括发行强制性可转换债券(MCB)、大股东借款 转股以及长期团队股权激励计划等。上述计划将在10月31日召开的特别股东大会上寻求批准。 金科的破产重整方案包括三部分：上限5万的小额债权现金偿付、每百元债权转2.53股、每百元债权转 100份信托收益权。对于债权的回收率，金科给出了明确的计算逻辑：(现金清偿金额+债转股的股数×股 价+信托受益权份额×单份资产价值0.019元/份)÷普通债权总金额。按此计算逻辑，对于大额的债务人来 说，回收率影响最大的便是金科的股价波动。以1000万债权为例，如果按当下金科股价1.38元/股计 算，可回收5万现金+市值约34.74万股票+约18.9万信托资产价值，合计58.64万，回收率不到6%；如果 金科股价上涨至其财务顾问对股权价值预估的6.46元/股(即股价上涨4.7倍)，则可回收5万现金+市值约 162.6万股票+约18.9万信托资产价值，合计186.5万，回收率可超18%。 考虑融创与旭辉均未给出明确的回收率测算逻辑， ...

智通财经APP讯，信达生物(01801)发布公告，于2025年10月22日(香港时间)，信达生物与武田制药(透过 武田制药全资附属公司Takeda Pharmaceuticals International AG)达成全球战略合作，旨在加速推进信达 生物新一代IO及ADC疗法开发，拓展全球市场价值。本次合作包括两款后期在研疗法IBI363 (PD-1/IL- 2α-bias)及IBI343 (CLDN18.2 ADC)，以及一款早期研发项目IBI3001 (EGFR/B7H3 ADC)的选择权。 根据合作，信达生物与武田制药将在全球范围内共同开发新一代IO基石疗法 IBI363 (PD-1/IL-2α-bias)， 并在美国共同商业化，武田制药将在共同治理和协同一致的开发计划下主导相关工作;同时，信达生物 授予武田制药IBI363在除大中华区及美国地区的商业化权益。信达生物授予武田制药IBI343 (CLDN18.2 ADC)在大中华区以外地区的独家权益。此外，信达生物授予武田制药IBI3001 (EGFR/B7H3 ADC)在大 中华区以外地区权益的独家选择权。 本公司将获得12亿美元的首付款，包括以认购事 ...